Orchard Therapeutics plc (NASDAQ:ORTX) has seen 1.04 million shares traded in the last trading session. The company, currently valued at $372.90M, closed the last trade at $2.93 per share which meant it lost -$0.16 on the day or -5.18% during that session. The ORTX stock price is -209.9% off its 52-week high price of $9.08 and 20.82% above the 52-week low of $2.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 0.87 million shares traded. The 3-month trading volume is 622.96K shares.
The consensus among analysts is that Orchard Therapeutics plc (ORTX) is a Buy stock at the moment, with a recommendation rating of 1.70. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 1 out of 10 have rated it as a Hold, with 8 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.33.
Orchard Therapeutics plc (NASDAQ:ORTX) trade information
Sporting -5.18% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Friday, 09/03/21 when the ORTX stock price touched $2.93 or saw a rise of 7.86%. Year-to-date, Orchard Therapeutics plc shares have moved -32.18%, while the 5-day performance has seen it change 2.45%. Over the past 30 days, the shares of Orchard Therapeutics plc (NASDAQ:ORTX) have changed -2.01%. Short interest in the company has seen 4.83 million shares shorted with days to cover at 11.47.
Wall Street analysts have a consensus price target for the stock at $11.44, which means that the shares’ value could jump 74.39% from current levels. The projected low price target is $8.00 while the price target rests at a high of $15.00. In that case, then, we find that the current price level is -411.95% off the targeted high while a plunge would see the stock gain -173.04% from current levels.
Orchard Therapeutics plc (ORTX) estimates and forecasts
Figures show that Orchard Therapeutics plc shares have outperformed across the wider relevant industry. The company’s shares have lost -62.48% over the past 6 months, with this year growth rate of 22.22%, compared to 7.50% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 31.20% and -25.00% for the next quarter. Revenue growth from the last financial year stood is estimated to be 164.00%.
8 analysts offering their estimates for the company have set an average revenue estimate of $260k for the current quarter. 7 have an estimated revenue figure of $5.1 million for the next quarter concluding in Sep 2021. Year-ago sales stood $597k and $110k respectively for this quarter and the next, and analysts expect sales will shrink by -56.40% for the current quarter and 4,536.40% for the next.
Orchard Therapeutics plc is expected to release its next earnings report between August 04 and August 09 this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Orchard Therapeutics plc (NASDAQ:ORTX)’s Major holders
Insiders own 0.12% of the company shares, while shares held by institutions stand at 68.91% with a share float percentage of 68.99%. Investors are also buoyed by the number of investors in a company, with Orchard Therapeutics plc having a total of 105 institutions that hold shares in the company. The top two institutional holders are RA Capital Management, L.P. with over 12.32 million shares worth more than $89.41 million. As of Mar 30, 2021, RA Capital Management, L.P. held 9.95% of shares outstanding.
The other major institutional holder is Artisan Partners Limited Partnership, with the holding of over 10.64 million shares as of Mar 30, 2021. The firm’s total holdings are worth over $77.27 million and represent 8.60% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Artisan Small Cap Fund and JP Morgan Small Cap Growth Fund. As of Mar 30, 2021, the former fund manager holds about 4.02% shares in the company for having 4.97 million shares of worth $36.08 million while later fund manager owns 1.61 million shares of worth $11.66 million as of Mar 30, 2021, which makes it owner of about 1.30% of company’s outstanding stock.